This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in other bacterial infections기타 세균감염을 유발한 HIV 감염병 (HIV 세균감염증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: B20.1 (HIV disease resulting in other bacterial infections) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration)
B. SynonymsHIV bacterial infection, HIV opportunistic bacterial infection, HIV-associated bacterial infections, HIV-associated recurrent bacterial pneumonia
C. Adult onsetLikelihood of first onset in adulthood: very high — occurs throughout life in HIV-infected adults, and recurrent bacterial pneumonia, Salmonella bacteremia, and nocardiosis occur at high frequency especially in adulthood (30s–60s) when immunosuppression has progressed.
1. HistoryRecognition of vulnerability to bacterial infection after the description of AIDS in 1981 → surge of pneumococcal pneumonia in HIV patients in the 1980s → recurrent bacterial pneumonia added in 1993 as a CDC AIDS-defining illness → decrease of bacterial infection after the introduction of ART in 1996 → further decrease of pneumococcal infection with expanded vaccination.
2. CausesMain pathogens: Streptococcus pneumoniae (pneumococcus; pneumonia, bacteremia), Haemophilus influenzae, nontyphoidal Salmonella (bacteremia), Nocardia (lung, brain), Staphylococcus aureus (skin, lung, bacteremia), gram-negative enteric bacteria (pneumonia, urinary tract infection). Impaired antibody-mediated immunity due to HIV is central to vulnerability to encapsulated bacteria.
3. GeneticsCCR5-Δ32 and HLA genes involved in HIV susceptibility. Pneumococcal susceptibility: Fc-γ receptor polymorphisms, mannose-binding lectin (MBL2) deficiency. Salmonella susceptibility: NRAMP1 polymorphism. Nocardiosis: associated with defects in the IL-12/IFN-γ pathway.
4. General epidemiologyThe frequency of bacterial pneumonia in HIV patients is 10–25 times that of the general population. Invasive pneumococcal infection is 5–100 times. Markedly decreased after ART. Nontyphoidal Salmonella bacteremia occurs 100–1,000 times more frequently in HIV than in immunocompetent individuals. Recurrent bacterial pneumonia (two or more times a year) was a CDC AIDS-defining illness in 1993. The status of bacterial infection in HIV patients in Korea is directly related to the distribution of CD4 counts and ART adherence.
5. PathophysiologyHIV → B-cell dysfunction (lack of functional antibodies despite hypergammaglobulinemia) → impaired opsonization of encapsulated bacteria (pneumococcus, H. influenzae) → recurrent invasive infection. Impaired gut epithelial immunity → easier mucosal invasion by Salmonella. Decreased CD4 → impaired clearance of Nocardia. After ART initiation, bacterial infection may transiently worsen due to IRIS.
6. SymptomsBacterial pneumonia: fever, purulent sputum, chest pain, dyspnea. Bacteremia (pneumococcus, Salmonella): high fever, chills, hypotension, sepsis. Nontyphoidal Salmonella bacteremia: bacteremia can occur even without fever, diarrhea, or abdominal pain. Nocardiosis: lung (cough, fever), brain (headache, focal neurological deficits), skin (subcutaneous abscess).
7. SignsChest X-ray: lobar infiltrate (pneumococcus), ground-glass opacity, bilateral infiltrates. Positive blood culture. Elevated CRP and PCT. Sputum Gram stain and culture. Salmonella bacteremia: positive blood culture; unlike typhoid fever, nontyphoidal infection can involve multiple organs. Nocardia: nodules/cavities on chest CT, brain abscess.
8. ScreeningNo screening of the general population. Check the history of pneumococcal vaccination in HIV patients (PCV13 + PPSV23). Hib vaccination recommended. Prompt evaluation including bacterial culture when pneumonia symptoms occur. Intensity of surveillance determined by risk stratification according to CD4 count.
9. DiagnosisBlood culture (bacteria, bacteremia), sputum culture, pneumococcal urinary antigen, Legionella urinary antigen. Nocardia: sputum/BAL/tissue culture (relatively slow growth — culture for 2–4 weeks needed), bronchoscopy, brain MRI (brain abscess). Salmonella: blood culture, stool culture. Bone marrow biopsy in disseminated infection.
10. TreatmentBacterial pneumonia: β-lactam + macrolide or respiratory fluoroquinolone (according to resistance test results). Salmonella bacteremia: ciprofloxacin or ceftriaxone for 2–6 weeks. Nocardiosis: TMP-SMX ± amikacin ± imipenem (triple therapy with brain involvement). Combined ART is essential in all cases.
11. PrognosisBacterial pneumonia (pneumococcus): mortality in the ART era about 5–20% (depending on CD4 count). Salmonella bacteremia has high mortality if untreated and improves with appropriate antibiotic treatment. High mortality with Nocardia brain involvement. Recurrent infection is the main cause of morbidity, and vaccination and ART are key.
12. PreventionPneumococcal vaccine (PCV20 or PCV15 + PPSV23), Hib vaccine, annual influenza vaccine. Maintain CD4 with ART. Consider TMP-SMX secondary prophylaxis in patients with recurrent pneumonia. Food hygiene management (prevention of Salmonella). Ciprofloxacin secondary prophylaxis to prevent recurrence of Salmonella bacteremia.
13. ReferencesPanel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections. AIDSinfo. 2023 … and 9 other papers

1. History

The association between HIV infection and bacterial infection was recognized from the early days of AIDS. After the first report of AIDS cases in the US CDC's MMWR in 1981, evidence quickly accumulated that pneumococcal (Streptococcus pneumoniae) pneumonia and bacterial sepsis occur at a markedly higher frequency in HIV patients than in immunocompetent individuals. In particular, invasive pneumococcal infection occurred 5 to 100 times more often in HIV patients than in the general population and was characterized by repeated recurrence.

When the US CDC revised the AIDS surveillance case definition in 1993, recurrent bacterial pneumonia (two or more episodes of bacterial pneumonia within 12 months) was added as an AIDS-defining illness. This formally acknowledged the importance of bacterial infection in the morbidity and mortality of HIV-infected individuals. Nontyphoidal Salmonella bacteremia was also included as an AIDS-defining illness in the same year.

After the introduction of highly active ART in 1996, the incidence of bacterial infection in HIV patients decreased markedly. However, in patients who do not receive ART or have poor adherence, bacterial infection remains a major cause of death. Since the 2000s, increasing MRSA (methicillin-resistant Staphylococcus aureus) infection in HIV patients and antimicrobial resistance of gram-negative bacteria have emerged as new clinical challenges.

In terms of prevention, the development of pneumococcal conjugate vaccines (PCV) is important. With the approval of PCV13 in 2010 and PCV15 and PCV20 for adults in 2021, the effect of preventing invasive pneumococcal infection in HIV patients has improved further. Korean HIV treatment guidelines also recommend pneumococcal vaccine, influenza vaccine, and Hib vaccine as essential vaccinations for HIV patients.


2. Causes

B20.1 covers HIV-related infections caused by other bacteria, excluding mycobacteria. The main pathogens and clinical syndromes are as follows.

Streptococcus pneumoniae (pneumococcus): the most common cause of bacterial pneumonia in HIV patients and the leading cause of community-acquired pneumonia. Invasive pneumococcal disease (IPD) with bacteremia occurs at a markedly higher rate than in the general population. HIV impairs the production of opsonic antibodies against capsular polysaccharide, resulting in recurrent infection.

Haemophilus influenzae: nontypeable H. influenzae is a cause of pneumonia and bacteremia in HIV patients. Hib (type b) infection can also occur in patients who have not received the Hib vaccine.

Nontyphoidal Salmonella (NTS): in immunocompetent individuals it mainly causes self-limited enteritis, but in HIV patients (especially CD4 <200/μL) it progresses to invasive infection such as bacteremia, endocarditis, and osteomyelitis. NTS bacteremia was designated a CDC AIDS-defining illness in 1993.

Nocardia genus (nocardiosis): Nocardia asteroides complex is the main causative organism. It causes lung (nodular and cavitary lesions), central nervous system (brain abscess), skin (subcutaneous abscess), and disseminated infection. It occurs mainly at CD4 <100/μL.

Staphylococcus aureus: cause of skin and soft tissue infection, pneumonia, bacteremia, and endocarditis. MRSA infection is a particular problem in HIV patients who inject drugs.

Others: include Pseudomonas aeruginosa (pneumonia, bacteremia; CD4 <50/μL), Bartonella quintana/henselae (cutaneous angiomatosis, peliosis), Listeria monocytogenes (meningitis, bacteremia), and gram-negative enteric bacteria (urinary tract infection, pneumonia).


3. Genetics

The genetic factors involved in vulnerability to bacterial infection in HIV infection are broadly divided into genes for susceptibility to HIV itself and genes for susceptibility to bacterial infection.

Regarding HIV susceptibility, the CCR5-Δ32 deletion variant of the CCR5 co-receptor gene (homozygotes are strongly resistant to HIV infection) and HLA genotypes (HLA-B*57:01 — associated with suppression of viral replication; HLA-B*35 — associated with rapid AIDS progression) are important.

Genes known to be related to susceptibility to invasive pneumococcal infection include Fc-γ receptor (FCGR2A, etc.) polymorphisms. Studies suggest that the FCGR2A His131 variant reduces IgG opsonization function against pneumococcal polysaccharide and raises the risk of invasive infection. Deficiency of mannose-binding lectin (MBL, MBL2 gene) increases innate immune vulnerability to encapsulated bacteria.

Regarding Salmonella susceptibility, SLC11A1 (NRAMP1) gene polymorphism is associated with suppression of Salmonella within macrophages. Nocardiosis can occur independently of HIV infection in patients with genetic defects of the IL-12/23–IFN-γ pathway (IL-12Rβ1, IFN-γR1/R2 mutations), and HIV-related CD4 T-cell depletion greatly worsens this vulnerability.

Regarding susceptibility to MRSA, immunoglobulin gene polymorphisms and neutrophil function-related genes have been studied, but no established specific marker exists. Clinically, injection drug use, history of hospitalization, and prior antimicrobial exposure, rather than HIV itself, are the major risk factors for MRSA infection.


4. General epidemiology

The incidence of bacterial infection in patients with HIV infection is markedly higher than in the general population. Bacterial pneumonia is one of the most common bacterial infections in patients with HIV; in the pre-ART era, its annual incidence was 10 to 25 times that of the general population. Invasive pneumococcal infection (bacteremia, meningitis) occurred 5 to 100 times more often than in the general population. Since the introduction of ART, these figures have decreased substantially, but a high risk persists in patients with CD4 <200/μL.

Non-typhoidal Salmonella bacteremia is one of the most common bacterial opportunistic infections in patients with HIV in Africa; in some African cohorts, the annual incidence in patients with HIV is reported to be 100 to 1,000 times higher than in the general population. In Asia and Korea as well, Salmonella bacteremia occurs in patients with HIV who have low CD4 counts.

According to Korean HIV epidemiologic data, opportunistic infections as a whole have decreased since the introduction of ART, but bacterial infections still occur in patients who enter ART late. As of 2022, about 20 to 30% of newly reported HIV cases in Korea are already diagnosed in an advanced immunodeficient state with CD4 <200/μL, so a group at high risk of bacterial opportunistic infection exists.

Nocardiosis is an opportunistic infection that is not uncommon in patients with HIV, and its frequency in patients with HIV is tens of times higher than in immunocompetent persons. Worldwide, about 35% of nocardiosis in patients with HIV is reported to show disseminated infection.


5. Pathophysiology

The increased vulnerability to bacterial infection caused by HIV infection is explained by combined impairment of multiple immune mechanisms.

B-cell dysfunction: Functional abnormalities of B cells appear from the early stage of HIV infection. Reduced CD4 T-cell helper signals decrease antigen-specific B-cell responses and reduce memory B cells. Paradoxically, total immunoglobulin (IgG) levels increase (hypergammaglobulinemia), but the quality and quantity of functional antibodies (especially opsonizing antibodies against capsular polysaccharides) are deficient. As a result, opsonization of encapsulated bacteria (Streptococcus pneumoniae, H. influenzae) is insufficient, and complement-phagocyte bactericidal function is reduced.

Mucosal immune impairment: HIV depletes CD4 T cells in gut-associated lymphoid tissue (GALT) early, weakening the intestinal epithelial immune barrier. As a result, enteric bacteria such as Salmonella can invade the mucosa and lead to bacteremia.

Neutrophil dysfunction: In advanced HIV infection, neutrophil count and function (chemotaxis, phagocytosis, oxidative burst) decline, reducing bacterial killing capacity. The risk of Pseudomonas and Nocardia infections is particularly related to this.

CD4 T-cell depletion: As the CD4 count falls, Th1 immunity (macrophage activation, IFN-γ production) declines, and defense against pathogens requiring intracellular killing (Nocardia, Salmonella) collapses.

IRIS: When immunity recovers rapidly after starting ART, an excessive inflammatory response to previously suppressed bacterial infection may occur, and clinical symptoms may transiently worsen.


6. Symptoms

Bacterial pneumonia (including Streptococcus pneumoniae, H. influenzae, and gram-negative bacteria): Sudden-onset fever (38.5°C or higher), chills, purulent sputum, pleuritic chest pain, and dyspnea are typical. In patients with HIV, pneumococcal pneumonia is more often accompanied by bacteremia than in the general population. Recurrent pneumonia (2 or more episodes within 12 months) is an AIDS-defining illness and suggests progression of HIV infection. Atypical pneumonia (Mycoplasma, Chlamydia) can also occur in patients with HIV.

Non-typhoidal Salmonella bacteremia: Fever (often 39°C or higher), chills, and fatigue are the main symptoms. In patients with HIV, bacteremia commonly occurs without being preceded by enteritis symptoms (diarrhea, abdominal pain) as seen in immunocompetent persons. Recurrent bacteremia is also frequent.

Nocardiosis: Pulmonary nocardiosis presents mainly with cough, fever, and chest pain, resembling tuberculosis or other pulmonary opportunistic infections. Cerebral nocardiosis presents with headache, focal neurologic deficits, seizures, and altered consciousness. Cutaneous nocardiosis forms subcutaneous abscesses, skin ulcers, and fistulas. In patients with HIV, disseminated infection (lung + brain or lung + skin) is common.

Other bacterial infections: Bartonella infection presents as systemic angiomatosis (bacillary angiomatosis), peliosis hepatis, and bacteremia. Staphylococcus aureus bacteremia can lead to serious complications such as endocarditis, septic arthritis, and osteomyelitis.


7. Signs

Bacterial pneumonia: Chest X-ray shows lobar pneumonic infiltrates or multifocal infiltrates. At CD4 <200/μL, a bilateral, ground-glass opacity pattern is more common. Pneumococcal urinary antigen (sensitivity ~60-80%, specificity >95%) is useful for rapid diagnosis. Streptococcus pneumoniae, H. influenzae, and others are isolated from blood cultures. CRP and PCT (procalcitonin) are markedly elevated in bacterial pneumonia.

Salmonella bacteremia: Isolation of Salmonella enterica (non-typhoidal, such as typhimurium and enteritidis) from blood culture is the confirmatory criterion. Complete blood count shows neutrophilia or neutropenia (in advanced immunodeficiency) and thrombocytopenia. Abdominal ultrasound or CT may show hepatosplenomegaly and lymph node enlargement.

Nocardiosis: Chest CT shows multiple nodules, cavities, consolidation, and pleural effusion. Isolation of Nocardia from sputum or BAL (bronchoalveolar lavage) culture (culture takes 2 to 4 weeks or more). Brain MRI shows single or multiple brain abscesses. Modified Kinyoun stain shows weakly acid-fast bacilli. Tissue biopsy is characterized by branching gram-positive acid-fast filamentous bacteria.

CD4 T-cell count: A key indicator for judging the level of risk of bacterial infection.


8. Screening

There is no separate systematic screening program for other bacterial infections in patients with HIV, but surveillance strategies to reduce the risk of bacterial infection are important in clinical practice.

Checking vaccination history: At the first visit, check the history of pneumococcal conjugate vaccine (PCV13, PCV15, or PCV20), 23-valent pneumococcal polysaccharide vaccine (PPSV23), Hib vaccine, and influenza vaccine (annual) in all patients with HIV, and administer them immediately if not yet received. Live vaccines (varicella, MMR, etc.) are in principle contraindicated when CD4 <200/μL, but inactivated and conjugate vaccines can be given even in an immunocompromised state (although the response may be reduced).

Clinical surveillance: When symptoms suggesting bacterial infection such as fever, cough, and chest pain appear in patients with HIV, perform blood cultures, chest X-ray, and sputum tests immediately. In patients with recurrent pneumonia, check the CD4 count and consider optimizing ART. Keep in mind the possibility of non-typhoidal Salmonella bacteremia in patients with a history of travel to or residence in other countries (especially Africa and Southeast Asia).

Maintaining the CD4 count through monitoring of ART adherence is the fundamental screening strategy for preventing bacterial opportunistic infection.


9. Diagnosis

Bacterial pneumonia: Sputum Gram stain and culture (limited sensitivity), blood culture (positive when bacteremia is present), pneumococcal urinary antigen test (BinaxNOW, etc.), Legionella urinary antigen test, and chest CT are included in the standard workup. Mycoplasma and Chlamydia serologic tests may be added to differentiate atypical pneumonia. BAL via bronchoscopy is performed when the diagnosis is uncertain or there is no response.

Salmonella bacteremia: Blood culture is key, and drawing blood during fever immediately after symptom onset increases the positive rate. When the organism is isolated, perform serotyping (Salmonella Typhimurium, Enteritidis, etc.) and antimicrobial susceptibility testing (resistance to fluoroquinolones and cephalosporins). Add stool culture if enteritis symptoms are present.

Nocardiosis: Culture from sputum, BAL, pleural fluid, cerebrospinal fluid, skin tissue, etc. is the reference diagnosis. Because Nocardia grows slowly in standard culture, maintain the culture for 4 to 6 weeks or more. Weakly acid-fast bacilli are confirmed with modified Kinyoun or modified Ziehl-Neelsen stain. Species identification of the isolated Nocardia (MALDI-TOF or 16S rRNA gene analysis) is important for drug selection.

Bartonella: Diagnosed by blood culture (prolonged culture of 5 weeks or more), serum antibody test (IFA), and tissue biopsy (Warthin-Starry stain, immunohistochemistry, PCR).


10. Treatment

Treatment of bacterial pneumonia: Empirical antimicrobial therapy for community-acquired pneumonia uses a β-lactam (amoxicillin/clavulanic acid, cephalosporin) + a macrolide (azithromycin, clarithromycin), or a respiratory fluoroquinolone (levofloxacin, moxifloxacin) alone. Severe pneumonia with bacteremia is treated with a third-generation cephalosporin (ceftriaxone) + a macrolide or an antipneumococcal fluoroquinolone, and treatment is adjusted according to culture and antimicrobial susceptibility results. When MRSA pneumonia is suspected, add vancomycin or linezolid.

Treatment of Salmonella bacteremia: Ciprofloxacin 500-750 mg twice daily (or 400 mg IV twice daily) or ceftriaxone 2 g/day IV is given for 2 to 6 weeks. The duration of treatment is determined by the site of the lesion (2 weeks for simple bacteremia; 4 to 6 weeks when complications such as osteomyelitis or endocarditis are present) and by whether resistance is present. To prevent recurrence, secondary prophylaxis with ciprofloxacin is considered when CD4 <200/μL.

Treatment of nocardiosis: TMP-SMX (trimethoprim-sulfamethoxazole) is the first-line treatment. Mild to moderate disease with pulmonary involvement only: TMP-SMX alone for 6 to 12 months. Severe or disseminated infection/CNS involvement: initial triple therapy with TMP-SMX + amikacin + imipenem/meropenem, then switch to maintenance therapy. Brain abscess may require surgical drainage. The duration of treatment is at least 6 months, and continues for 12 months or more in the immunocompromised state.

Optimizing ART in all bacterial infections is essential for preventing recurrence through immune recovery and for curing the infection.


11. Prognosis

The prognosis of HIV-associated bacterial infections has improved greatly in the ART era, but it varies according to the type of infection, CD4 count, presence of antimicrobial resistance, and speed of diagnosis.

Bacterial pneumonia: In the pre-ART era, in-hospital mortality of bacterial pneumonia in patients with HIV was about 10-30%, but in the ART era it has decreased to 5-15%. Mortality is higher when CD4 <50/μL or bacteremia is present. Pneumococcal vaccination and CD4 recovery by ART are key to preventing recurrence.

Salmonella bacteremia: Most patients improve with appropriate antimicrobial treatment, but the recurrence rate is high (about 40-50% without ART). CD4 recovery through ART greatly lowers the risk of recurrence. The prognosis is worse in infection with antimicrobial-resistant (fluoroquinolone-resistant, ESBL-producing) Salmonella.

Nocardiosis: Nocardiosis confined to the lung has a relatively good prognosis with TMP-SMX treatment. Disseminated infection with CNS involvement has a mortality of 40-50%, and survivors may have neurologic sequelae. Early diagnosis and concurrent ART are important for improving prognosis.


12. Prevention

Vaccination: Giving a single dose of pneumococcal conjugate vaccine (PCV20 or PCV15) to all adult patients with HIV, and adding PPSV23 at least 8 weeks after PCV15, is recommended in the 2021 US ACIP guidelines. A single dose of Hib vaccine may be considered in adults with HIV who have not formed antibodies. Influenza vaccine is given annually.

Salmonella prevention: Minimize Salmonella exposure through food hygiene education (thorough cooking before eating; separating raw meat, poultry, and eggs from cooked food). In patients with recurrent Salmonella bacteremia and CD4 <200/μL, consider prophylactic ciprofloxacin.

Prophylactic TMP-SMX: TMP-SMX given for PCP prophylaxis in patients with HIV and CD4 <200/μL also provides a preventive effect against bacterial infections (Salmonella, Nocardia, some pneumococcal infections, etc.). In developed countries including Korea, TMP-SMX prophylaxis is a standard recommendation for all patients with HIV and CD4 <200/μL.

Early initiation of ART: Keeping the CD4 count high is the fundamental strategy for preventing bacterial infections overall, through recovery of B-cell function, improvement of neutrophil function, and recovery of Th1 immunity.


13. References

  1. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. AIDSinfo. Updated 2023. Available at: clinicalinfo.hiv.gov.

  2. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005;165(13):1533-1540. DOI: 10.1001/archinte.165.13.1533. PMID: 16009869.

  3. Gordon MA, Banda HT, Gondwe M, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS. 2002;16(12):1633-1641. DOI: 10.1097/00002030-200208160-00009. PMID: 12172087.

  4. Filice GA. Nocardiosis in persons with human immunodeficiency virus infection, transplant recipients, and large, geographically defined populations. Medicine (Baltimore). 2010;89(4):227-246. DOI: 10.1097/MD.0b013e3181e5fa89. PMID: 20616664.

  5. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341-1348. DOI: 10.1056/NEJMoa035060. PMID: 14523142.

  6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505. DOI: 10.1056/NEJMoa1105243. PMID: 21767103.

  7. Tumbarello M, Tacconelli E, de Gaetano K, et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr. 1998;18(1):39-45. DOI: 10.1097/00042560-199805010-00006. PMID: 9593449.

  8. Kim JM, Cho GJ, Hong SK, et al. Epidemiology and clinical features of HIV infection/AIDS in Korea. Yonsei Med J. 2003;44(3):363-370. DOI: 10.3349/ymj.2003.44.3.363. PMID: 12833573.

  9. Guerrant RL, Thielman NM. Non-typhoidal salmonellosis and bacteremia in HIV-infected patients. Clin Infect Dis. 1997;25(Suppl 2):S169-S176. DOI: 10.1086/516215. PMID: 9310655.

  10. Trevenzoli M, Cattelan AM, Rea F, et al. Nocardiosis in HIV-infected patients: report of 12 cases and review of the literature. Eur J Clin Microbiol Infect Dis. 2002;21(1):62-67. DOI: 10.1007/s10096-001-0650-4. PMID: 11855923.